Search Results

You are looking at 21 - 30 of 1,605 items for :

Clear All
Free access

Andrew W Norris, Katie Larson Ode, Lina Merjaneh, Srinath Sanda, Yaling Yi, Xingshen Sun, John F Engelhardt and Rebecca L Hull

Example Disease Pancreatic insufficiency risk (Ahmed et al . 2003) Diabetes risk (Adler et al . 2008) I Failed synthesis G542X Severe High High II Failed protein processing F508del Severe High High III

Free access

Craig S Nunemaker, H Grace Chung, Gretchen M Verrilli, Kathryn L Corbin, Aditi Upadhye and Poonam R Sharma

Introduction Chronic low-grade inflammation is increasingly considered as a contributing factor to many metabolic diseases including type 2 diabetes (T2D). Obesity leads to excess fatty acids and lipids in the body, which have toxic and damaging

Free access

Mathis Grossmann

Introduction: significance of the clinical problem Around 50% of ageing, obese men presenting to the diabetes clinic have lowered testosterone levels relative to reference ranges based on healthy young men ( Grossmann 2011 ). Many have symptoms

Free access

Weiwei Xu, Jamie Morford and Franck Mauvais-Jarvis

particularly surprising, as observational studies have implicated low testosterone levels in both the development of insulin resistance and the pathogenesis of hyperglycemia and diabetes in men, and hyperglycemia requires β cell dysfunction to develop. In the

Free access

Henrik Ortsäter, Nina Grankvist, Richard E Honkanen and Åke Sjöholm

Type 2 diabetes: a growing epidemic Type 2 diabetes (T2D) is a syndrome characterized by disordered metabolism, resulting in hyperglycemia. The most common and dreaded long-term complication of diabetes is cardiovascular disease, which accounts for

Free access

Libor Vítek and Martin Haluzík

-acting hormones ( Potthoff et al . 2012 ). Interestingly, when administered in pharmacological doses, both FGF19 and FGF21 have insulin-sensitizing and hypolipidemic effects in rodent models of obesity and type 2 diabetes (T2DM) ( Tomlinson et al . 2002

Free access

Mohamed Lotfy, Jaipaul Singh, Hameed Rashed, Saeed Tariq, Erika Zilahi and Ernest Adeghate

Introduction Diabetes mellitus (DM) is a major metabolic disorder and a global health problem currently affecting more than 250 million people worldwide ( Zimmet & Alberti 2006 ). Type 1 and type 2 DM (T1DM and T2DM) can lead to a number of long

Free access

Wenpeng Dong, Ye Jia, Xiuxia Liu, Huan Zhang, Tie Li, Wenlin Huang, Xudong Chen, Fuchun Wang, Weixia Sun and Hao Wu

Introduction As one of the long-term complications of diabetes, diabetic nephropathy (DN) is the main cause of end-stage renal disease ( Dronavalli et al . 2008 ). Thus, end-stage renal disease cannot be effectively prevented or treated

Free access

Prabhakara R Nagareddy, Sunil K Noothi, Michelle C Flynn and Andrew J Murphy

such as diabetes and metabolic syndrome to promote an exacerbated myelopoietic phenotype. The mechanisms of each of these risk factors in relation to myeloid-driven CAD are summarized in Fig. 1 (modified from Murphy & Tall 2016 ) and detailed below

Free access

P Brandimarti, J M Costa-Júnior, S M Ferreira, A O Protzek, G J Santos, E M Carneiro, A C Boschero and L F Rezende

Introduction Type 2 diabetes is a complex illness mainly characterized by hyperglycemia, usually accompanied by pancreatic islets malfunction, and reduced insulin sensitivity, as well as lower insulin clearance. Although hyperglycemia is one of the